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Although obesity is associated with nonalcoholic fatty liver disease (NAFLD), the causal mechanisms are
unclear. In this issue, Imajo et al. (2012) show that, in mice, leptin enhances the effects of bacterial endotoxin,
promoting the development of NAFLD.Nonalcoholic fatty liver disease (NAFLD)
encompasses a range of liver disorders
having increased intracytoplasmic triglyc-
eride in hepatocytes (hepatic steatosis).
As the term NAFLD implies, there is no
identified cause of the hepatic steatosis,
such as ethanol consumption or use of
a steatotic medication. NAFLD without
hepatocellular injury is termed nonalco-
holic fatty liver (NAFL), while NAFLD with
inflammation and hepatocyte injury is
denoted nonalcoholic steatohepatitis
(NASH) (Chalasani et al., 2012). In adults,
the estimated prevalence of NAFLD
worldwide is 20% and that of NASH is
4% (Vernon et al., 2011). It is not known
what distinguishes those individuals with
NAFL who will progress to NASH from
those who are protected from progres-
sion. Similarly, it is unknown why some
NASH patients progress to cirrhosis while
most do not. Imajo et al. (2012) now iden-
tify a mechanism that promotes NASH in
mice. They show that, in a mouse model
of steatosis, high leptin levels increase
the levels of CD14, an innate immune
receptor that recognizes bacterial lipo-
polysaccharide (LPS). High CD14 levels,
in turn, promote inflammation, leading
to NASH.
Given that obesity is the largest risk
factor for increased liver triglyceride
content, an increase in NAFL prevalence
is expected from the current epidemic in
obesity. Other risk factors for NASH
include insulin resistance, increased low-
density lipoprotein cholesterol, and meta-
bolic syndrome. However, the causal
mechanisms explaining the relationship
between NAFLD and these risk factors
are not clear at this time (Cohen et al.,
2011). This is in part due to the lack of
clearly predictive animal models (Heb-
bard and George, 2011). From first princi-
ples, the steatosis could be due toincreased fatty acids supplied by dietary
intake, adipose tissue release, and/or de
novo hepatic synthesis. Hepatic steatosis
could also be due to reduced removal of
triglyceride via fatty acid oxidation and/
or export as very low-density lipoprotein
particles. The inflammatory component
is similarly likely to be multifactorial, with
causes both linked to steatosis and inde-
pendent of it.
Imajo et al. (2012) studied a mouse
model in which the steatosis is induced
with a high-fat diet (HFD) and the inflam-
matory state with LPS. They demonstrate
that the HFD, in addition to increasing liver
triglyceride, also increases CD14-positive
Kupffer cell content. CD14 participates in
innate immunity, acting as a receptor for
and thus sensitizing cells to LPS. The
HFD mice were treated with the highest
dose of LPS that, in chow-fed controls,
did not increase markers of liver injury.
This same LPS dose did increase
liver triglyceride content, proinflammatory
cytokine expression, inflammatory cell
infiltration, and fibrosis when given to the
HFD mice. Furthermore, Imajo et al. also
show that the adipose-derived ‘‘adipo-
kine’’ hormone leptin increases Kupffer
cell CD14 expression, whereas deficiency
of leptin or leptin signaling protects
against increased CD14 expression, liver
inflammation, and fibrosis. Taken to-
gether, the data support the paradigm
that a HFD induces obesity and increases
leptin levels, thereby increasing Kupffer
cell CD14 levels and increasing sensitivity
to LPS-mediated hepatic inflammation
and injury.
Although leptin deficiency has a greater
effect on metabolic parameters than does
leptin excess, leptin’s effects on immune
responses and inflammation may not
follow the same pattern. For example,
the modest immune deficits of leptin-Cell Metabodeficient patients do not cause a clinically
significant immune deficiency phenotype
(Farooqi et al., 2002). In contrast, Imajo
et al. make a strong case for a permis-
sive—even causal—contribution of leptin
in their mouse NAFLD model. How
general is this result? Does it apply to
human NAFLD? Consistent with their
mouse observations, Imajo et al. present
human data showing a correlation
between hepatic CD14 mRNA levels and
serum leptin levels. In a BMI-matched
comparison, eight NASH patients had
higher hepatic CD14 mRNA and serum
leptin levels than did six non-NAFLD
controls. However, at least seven papers
have previously examined the correlation
between circulating leptin levels and
various measures of NAFLD in humans,
and once the correlation between leptin
and obesity is accounted for, there is no
consistent link between leptin and
NAFLD. Thus it remains unclear, from
these observational studies, whether an
increase in leptin levels actively promotes
NASH.
Possibly the most direct test of leptin’s
role is the leptin-deficient lipodystrophy
patients who suffer from NAFLD (Javor
et al., 2005). Lipodystrophy patients
have a genetically, inflammatory-, or
autoimmune-mediated deficiency of
adipose tissue and thus low leptin levels.
The paucity of adipose tissue also leads
to ectopic triglyceride deposition,
including hepatic steatosis. When leptin
was administered to lipodystrophy
patients with NASH, the liver disease
improved dramatically, with 6 of 8
patients no longer meeting the NASH
diagnostic criteria, suggesting that in
these cases leptin reversed the NASH.
There are a number of possible explana-
tions for the apparently opposite effects
of leptin reported by Imajo et al. and bylism 16, July 3, 2012 ª2012 Elsevier Inc. 1
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model of NASH may be a special case,
mouse NASH may be fundamentally
a poor model of human NASH, or the
NASH in lipodystrophy may be unrepre-
sentative of ‘‘typical’’ NASH due to inade-
quate adipose tissue storage capacity. To
determine which (if any) of these explana-
tions is correct will require a deeper
understanding of NASH.
A starting point might be detailed phe-
notyping and classification of NAFLD
using criteria in addition tomedical history
and histology. Comparison with cancer is
illustrative: by exquisitely genotyping and
phenotyping cancers, treatments can
now be tailored, thus yielding a higher
probability of treatment success and
less toxicity. A similar analysis of NAFLD
may identify subclasses of the disease
with unique immune, inflammatory, and
metabolic characteristics and may reveal
whether leptin plays the same or different
roles in each type. Genetic screens have
now identified six loci that contribute to
variance in NAFLD traits (e.g., Romeo2 Cell Metabolism 16, July 3, 2012 ª2012 Elset al., 2008; Speliotes et al., 2011), with
one increasing hepatic triglyceride
production (Kumari et al., 2012), suggest-
ing that further phenotyping efforts will be
fruitful. It seems likely that integrating
phenotypic and genetic information with
mechanistic studies will help unravel the
conundrum that is NASH. In summary,
Imajo et al. make a strong case that leptin
contributes to NASH in a mouse endo-
toxin model of NASH. This interesting
result will spur examination of the gener-
ality of the contribution of leptin in other
NASH models and drive more detailed
mechanistic studies of NAFLD.
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How adenosine receptors protect the ischemic heart is not completely understood. Eckle et al. (2012) now
show that signaling through adenosine receptor 2b (Adora2b) stabilizes a circadian rhythm protein, period
2 (Per2), resulting in the stabilization of hypoxia-inducible factor-1a (HIF-1a), upregulation of glycolysis,
and cardioprotection from ischemia.Myocardial ischemia results in dramatic
metabolic perturbations, due primarily
to a mismatch between cardiac muscle
oxygen supply and demand. The ensuing
deficits in ATP production can lead to
cardiac myocyte cell death. As such,
considerable efforts have focused on
modulating cardiac energy metabolism
as an approach to treat myocardial
ischemia. In addition to the many
approaches aimed at increasing energy
supply or decreasing energy demand,
novel approaches include switching theheart to a more ‘‘oxygen-efficient’’ utiliza-
tion of energy substrates (Lopaschuk
et al., 2010). Adenosine receptor signaling
has been extensively studied as an
approach to treat myocardial ischemia
(Eckle et al., 2008), with favorable alter-
ations in cardiac energy metabolism
contributing to the cardioprotective effi-
cacy of adenosine receptor activation
(Finegan et al., 1996).
A recent study (Eckle et al., 2012)
provides important insights into the sig-
naling pathways by which adenosinereceptor 2b (Adora2b) activation medi-
ates cardioprotection. The authors dem-
onstrate a selective upregulation of
Adora2b in clinical samples from patients
with ischemic heart disease. To delineate
the signaling pathways downstream of
Adora2b activation and their potential
role in cardioprotection the authors em-
ployed an ischemic preconditioning (IPC)
protocol (adenosine receptor activation
has been identified as a key component
of IPC), where brief, sublethal periods of
ischemia and reperfusion, prior to a
